华仁药业股份有限公司 2016 年第一季度报告 2016-051 2016 年 04 月 1 华仁药业股份有限公司 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)王文萍声明：保证季度报告中财务报告的真实、完整。 华仁药业股份有限公司 2016 年第一季度报告全文 2 华仁药业股份有限公司 2016 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 276,136,950.69 | 242,424,553.17 | 13.91% | | 归属于上市公司股东的净利润（元） | 2, ...

华仁药业股份有限公司 2015 年年度报告全文 华仁药业股份有限公司 2015 年年度报告 2016-042 2016 年 04 月 1 华仁药业股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主管人员)王文萍声明：保证 年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 梁福东 | 董事 | 工作原因 | 褚旭 | 1、 行业政策风险 随着医药卫生体制改革的不断推进，国家陆续出台一系列改革政策，这对医药行业既是挑战也是机遇。 对此，公司 2016 年将围绕"调整思路 创新模式"展开各项工作，努力捕捉市场变化带来的发展机遇。一方 面，不断健全产品结构，创新销售模式，提高资产周转率。另 ...

2015 年第三季度报告 2015-110 2015 年 10 月 1 华仁药业股份有限公司 2015 年第三季度报告全文 华仁药业股份有限公司 2015 年第三季度报告全文 华仁药业股份有限公司 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主管人员)王文萍声明：保证 季度报告中财务报告的真实、完整。 2 华仁药业股份有限公司 2015 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,611,029,775.16 | | 2,621,597,844.63 | -0.40% ...

华仁药业股份有限公司 2015 年半年度报告全文 华仁药业股份有限公司 2015 年半年度报告 2015-084 2015 年 08 月 1 华仁药业股份有限公司 2015 年半年度报告全文 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 公司负责人 梁富友、主管会计工作负责人王文萍及会计机构负责人(会计 主管人员)王文萍声明：保证本半年度报告中财务报告的真实、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 2015 | 半年度报告 1 | | --- | --- | | 第一节 | 重要提示、释义 1 | | 第二节 | 公司基本情况简介 4 | | 第三节 | 董事会报告 6 | | 第四节 | 重要事项 10 | | 第五节 | 股份变动及股东情况 14 | | 第六节 | 董事、监事、高级管理人员情况 15 | | 第七节 | 财务报告 16 | | 第八节 | 备查文件目录 76 | 华仁药业股份有限公司 ...

华仁药业股份有限公司 2014 年年度报告全文 华仁药业股份有限公司 2014 年年度报告 2015 年 04 月 1 华仁药业股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担个别及连带责任。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)王文萍声明：保证年度报告中财务报告的真实、准确、完整。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险 认识，并且应当理解计划、预测与承诺之间的差异。 2 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 蔡弘 独立董事 工作原因 王春波 | 目录 | | --- | | 2014 | 年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 6 | | 第二节 | 公司基本情况简介 ...

华仁药业股份有限公司 2015 年第一季度报告全文 华仁药业股份有限公司 2015 年第一季度报告 2014-038 2015 年 04 月 1 华仁药业股份有限公司 2015 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 除下列董事外，其他董事亲自出席了审议本次季报的董事会会议 | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 蔡弘 | 独立董事 | 工作原因 | 王春波 | 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)王文萍声明：保证季度报告中财务报告的真实、完整。 2 华仁药业股份有限公司 2015 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | ...

华仁药业股份有限公司 2014 年第三季度报告全文 华仁药业股份有限公司 2014 年第三季度报告 2014-046 2014 年 10 月 1 华仁药业股份有限公司 2014 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁富友、主管会计工作负责人王文萍及会计机构负责人(会计主管人员)王文萍声明：保证 季度报告中财务报告的真实、完整。 2 华仁药业股份有限公司 2014 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,437,988,639.16 | | 2,366,899,042.03 | 3.00% ...

Financial Performance - Total revenue for the first half of 2014 was CNY 408,341,088.34, representing a 12.21% increase compared to CNY 363,902,272.36 in the same period last year[17]. - Net profit attributable to shareholders decreased by 34.30% to CNY 32,219,932.82 from CNY 49,037,744.29 year-on-year[17]. - Basic earnings per share decreased by 28.57% to CNY 0.05 from CNY 0.07 in the same period last year[17]. - The company's net profit attributable to shareholders for the current period is CNY 32,219,932.82, a decrease of 34.30% compared to the previous period[24]. - Total operating revenue for the current period is CNY 408,341,088.34, representing a growth of 12.21% year-on-year[30]. - Operating costs increased by 19.85% to CNY 198,963,596.15, contributing to a decline in gross profit margin[32]. - Management expenses surged by 49.25% to CNY 72,210,586.17, primarily due to the amortization of equity incentive expenses amounting to CNY 21,683,400[32]. - Financial expenses rose by 45.23% to CNY 15,389,988.20, attributed to new loans totaling CNY 320 million[32]. - The company reported a significant decline in cash flow per share, which fell by 71.77% to CNY 0.0424 from CNY 0.1502 in the previous year[17]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,266,490,306.49, a decrease of 4.24% from CNY 2,366,899,042.03 at the end of the previous year[17]. - The company's total liabilities decreased from CNY 907,555,848.72 to CNY 797,214,900.75, a reduction of approximately 12.2%[125]. - The total equity attributable to shareholders increased slightly from CNY 1,459,343,193.31 to CNY 1,469,275,405.74, reflecting an increase of about 0.7%[125]. - The company's current assets totaled CNY 971,106,836.27, down from CNY 1,056,022,572.76, indicating a decrease of about 8.0%[123]. - The cash and cash equivalents decreased significantly from CNY 362,878,823.14 to CNY 164,362,314.43, a decline of approximately 54.7%[123]. Cash Flow - Net cash flow from operating activities fell by 56.22% to CNY 28,504,659.17, down from CNY 65,102,196.24 in the previous year[17]. - The company reported a net cash outflow from investing activities of 172,076,405.23 CNY, compared to a net outflow of 138,186,103.91 CNY in the previous period, indicating increased investment expenditures[138]. - Cash inflow from financing activities was 320,046,077.86 CNY, with cash outflow totaling 374,990,840.51 CNY, leading to a net cash outflow of 54,944,762.65 CNY[138]. Research and Development - Research and development investment increased by 71.20% to CNY 27,097,462.43, reflecting the company's commitment to enhancing R&D capabilities[32]. - The company's R&D investment totaled ¥27,097,500, accounting for 6.64% of total revenue, focusing on therapeutic and nutritional infusions, as well as blood purification products[42]. - The company established a blood purification product research station, enhancing its R&D capabilities in this area[44]. Market and Sales - The company faces risks including a slowdown in the infusion industry and potential sales volume shortfalls for blood purification products[25][26]. - The company plans to enhance its marketing strategies and improve sales team performance to mitigate risks associated with market conditions[25]. - The therapeutic infusion segment saw a revenue increase of 62.51% to ¥58,635,352.28, with a significant growth rate of 34.96% compared to the previous period[37]. - The company has developed new opportunities in product packaging and clinical applications to better meet the needs of hospitals and patients[48]. Shareholder Information - The company implemented a profit distribution plan, distributing a cash dividend of 1 RMB per 10 shares and increasing capital by 5 shares for every 10 shares held, resulting in a total share capital increase to 672.527235 million shares[71]. - The total number of shares increased from 448,351,490 to 672,527,235 due to a capital reserve conversion, resulting in a 50% increase in shares[106]. - The largest shareholder, Huarun Century Group, holds 50.63% of the shares, with 339,000,000 shares pledged[109]. Compliance and Governance - The company has maintained compliance with its commitments to shareholders, with no reported violations during the reporting period[102]. - There were no significant litigation or arbitration matters during the reporting period[77]. - The company did not engage in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[68][69][70]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development[148]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the H industry[178]. - A new strategy has been implemented to improve operational efficiency, aiming for a reduction in costs by I% over the next year[178].

Financial Performance - Total revenue for Q1 2014 was CNY 198,583,397.50, an increase of 23.49% compared to CNY 160,805,036.38 in the same period last year[8] - Net profit attributable to ordinary shareholders was CNY 28,704,710.76, representing a growth of 12.44% from CNY 25,530,041.08 year-on-year[8] - Basic earnings per share increased by 9.4% to CNY 0.0640, compared to CNY 0.0585 in the same period last year[8] - The total operating revenue for the first quarter of 2014 was CNY 141,800,346.23, an increase of 15.9% compared to CNY 122,273,942.18 in the same period last year[58] - The net profit attributable to the parent company was CNY 28,704,710.76, up from CNY 25,530,041.08, reflecting a growth of 8.6% year-over-year[56] - The total profit for the period was CNY 33,716,518.18, compared to CNY 30,989,878.11, indicating a growth of 8.8%[56] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 70.26% to CNY 8,669,227.71, down from CNY 29,146,399.89 in the previous year[8] - Cash and cash equivalents decreased by 35.25% compared to the beginning of the year, primarily due to the repayment of bank loans[23] - The company’s cash and cash equivalents decreased from 362,878,823.14 RMB at the beginning of the period to 234,953,236.65 RMB at the end of the period[47] - The company’s cash and cash equivalents decreased to CNY 126,168,436.07 from CNY 253,366,368.37 in the previous quarter[52] - The ending balance of cash and cash equivalents was 126,168,436.07 CNY, down from 138,951,427.68 CNY year-over-year[67] - The company reported a total tax payment of 24,078,338.83 CNY, an increase from 22,060,522.14 CNY in the previous year[66] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,285,956,546.15, a decrease of 3.42% from CNY 2,366,899,042.03 at the end of the previous year[8] - Current assets totaled CNY 876,612,823.49, down from CNY 1,000,833,368.80 in the previous quarter[52] - Total liabilities were CNY 731,414,672.15, down from CNY 838,383,791.61 in the previous quarter[53] - The company’s total assets decreased from 1,056,022,572.76 RMB to 1,006,719,125.07 RMB, reflecting a reduction in current assets[47] Operational Challenges and Risks - The company reported a significant risk of slowing sales growth due to new drug bidding policies and price control measures, which may impact overall revenue[10] - The company faces risks from declining drug bidding prices, which could reduce operating profits; it plans to implement differentiated bidding strategies to enhance winning rates and maintain product prices[28] - New business promotions in infusion and blood purification fields are slower than expected, prompting the company to hire professionals and integrate market resources to mitigate risks[29] - The company is experiencing labor shortages due to rapid capacity expansion and increased employee turnover; it is establishing long-term partnerships with vocational schools and offering competitive compensation to attract and retain talent[29] Shareholder Information - The company has a total of 19,341 shareholders, with the largest shareholder holding 50.53% of the shares[14] - The company’s board approved a dividend distribution plan of 1 RMB per 10 shares, along with a capital reserve increase of 5 shares for every 10 shares held[42] - The company has revised its profit distribution policy to ensure clarity and protect shareholder interests[42] Investment and Projects - The total amount of raised funds is CNY 71,402.97 million, with a total investment of CNY 69,641.87 million in the current quarter[38] - The investment progress of the non-PVC soft packaging large infusion project is 99.92%, with a total investment of CNY 22,153 million[38] - The blood purification engineering technology center project has an investment progress of 106.86%[38] - The company plans to complete the new GMP certification and commence production in the second quarter of 2014 for its technical renovation project[41] Management and Governance - The company plans to enhance its group management efficiency to mitigate risks associated with its rapid expansion and management control[12] - The company has committed to ensuring no competition with its actual controlling enterprises[36] - The company has fulfilled its commitments to minority shareholders in a timely manner[36]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2013, representing a year-on-year increase of 15%[17]. - Net profit for 2013 was 200 million RMB, which is a 10% increase compared to the previous year[17]. - The company achieved a gross margin of 45% in 2013, maintaining a stable performance in cost management[17]. - The company achieved operating revenue of CNY 867.20 million in 2013, a 54.3% increase compared to 2012[30]. - The total profit for the year was CNY 143.35 million, representing a 21.85% increase year-over-year[30]. - Net profit attributable to shareholders was CNY 121.52 million, up 25.81% from the previous year[30]. - The company generated a net cash flow from operating activities of CNY 39.78 million, a decrease of 60% compared to 2012[30]. - The total assets increased by 32.6% to CNY 2.37 billion at the end of 2013[30]. - The total liabilities rose by 103.63% to CNY 907.56 million, resulting in an asset-liability ratio of 38.34%[30]. - The company reported a net profit of CNY 80,173,450.24 for the year ending December 31, 2013, with a distributable profit of CNY 357,066,840.09 after statutory surplus reserves[97]. - The total cash dividend amount for 2013 is CNY 44,835,149.00, which represents 36.9% of the net profit attributable to shareholders[100]. Market Expansion and Product Development - User data indicated a growth in customer base by 20%, reaching a total of 500,000 active users by the end of 2013[17]. - The company plans to launch three new products in 2014, focusing on innovative drug formulations and expanding its therapeutic areas[17]. - Future outlook includes a projected revenue growth of 20% for 2014, driven by new product launches and market expansion strategies[17]. - The company aims to expand its market presence in Southeast Asia, targeting a 15% market share by 2015[17]. - The company plans to enhance product competitiveness and improve asset utilization to mitigate risks from industry price declines[26]. - The company plans to focus on blood purification and parenteral nutrition products as key R&D directions moving forward[56]. - The company is positioned as a professional manufacturer of large-volume preparations, with an annual production capacity of 530 million bags and a product range covering 135 specifications[88]. - The company aims to enhance its core competitiveness through market expansion and new product development, focusing on differentiated marketing strategies and innovative sales approaches[88]. Research and Development - Investment in R&D increased by 25% in 2013, reflecting the company's commitment to innovation and quality improvement[17]. - Research and development investment surged by 133.96% year-on-year, driven by payments related to the valsartan tablet project[40]. - The company has 23 drugs under research, with 14 already submitted for production and 1 in clinical trials[48]. - The company established an academic workstation for blood purification product research, marking a significant step in its R&D collaboration[48]. - The company’s R&D expenditure capitalization rate was 13.79%, indicating a strategic focus on enhancing its competitive edge[49]. - The company is transitioning its R&D focus from imitation to innovation, increasing investment in innovative drugs, and enhancing collaboration with research institutions[94]. Operational Efficiency - The implementation of a new warehouse management system (WMS) is expected to improve operational efficiency by 30%[17]. - The company is focused on improving operational efficiency and financial performance in the upcoming fiscal year[1]. - The company plans to improve asset utilization through resource integration and management of existing investment projects while conducting thorough investment evaluations for new projects[94]. Corporate Governance and Management - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 458.16 million[182]. - The company employed a total of 2,902 staff, with production personnel constituting 59.96% of the workforce[187]. - The total number of independent directors is six, each receiving a remuneration of CNY 10 million[183]. - The company’s governance structure is in compliance with the requirements set by the China Securities Regulatory Commission[190]. - The company has established a responsibility system for significant errors in annual report disclosures, which was approved during the 9th board meeting of the third session[194]. - The audit report issued by Zhongxinghua Accounting Firm provided a standard unqualified opinion on the financial statements for the year ending December 31, 2013[198]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance its market position and product portfolio[17]. - The company completed the acquisition of the remaining 30% stake in Shandong Jiejing Pharmaceutical Co., making it a wholly-owned subsidiary, and plans to complete the GMP certification for new production lines in the first half of 2014[37]. - The company formed partnerships with 62 commercial companies, enhancing its market influence and sales channels[32]. - The company has authorized a total of 44 patents, including both utility models and invention patents, during the reporting period[66]. - The company has a total of 1,920,580 shares held by Liang Fuyou, with 687,000 shares being newly granted under the equity incentive plan[167]. Financial Management - The company’s cash flow from financing activities increased by 622.3% to ¥487,629,399.03, primarily due to increased bank loans[53]. - Financial expenses increased by 497.97% due to higher bank loan interest, reflecting the company's strategy to finance growth through debt[40]. - The company’s leadership team has a strong background in the pharmaceutical and healthcare sectors, contributing to its strategic vision[172]. - The company has plans for further capital management strategies to optimize shareholder value[1].